https://www.selleckchem.com/pr....oducts/upadacitinib.
The use of primary cytoreduction should be considered in the place of interval cytoreduction for advanced mEOC.Introduction Repeat transurethral resection of bladder tumor (ReTURBT) has become an integral part of the management of superficial bladder cancers at various urological centers around the world. Early detection of residual disease, leading to upstaging in some cases, leads to decrease in recurrence rates. Our study aimed to analyze the impact of ReTURBT in detecting residual tumor and tumor recurrences, hence validating
Like
Comment
Share
